ALSO NOTED: CMA: Docs rely too much on pharma's spin; Faes licenses antihistamine to Italian firm;

> A Canadian Medical Association official says doctors get too much information about prescription drugs from the pharma companies themselves, and that there's a lack of impartial drug info. Report

> Spain's Faes Farma has licensed the marketing rights to its antihistamine drug Bilastina to the Italian firm Menarini. Report

> Health officials in the Phillipines say a recent compromise on prescription-drug prices isn't enough; they want the islands to nationalize their pharma industry. Report

> The FDA wants the over-the-counter spermicide nonoxynol-9 to carry a new warning: that the product does not protect against HIV and other sexually transmitted diseases. Report

> CV Therapeutics got the FDA's blessing on a new label for its angina drug Ranexa. Report

> Bioserve is hopping on the pharmacogenomics bandwagon. Report

> Analysts applauded Canada's BioMS after it scored a rich licensing deal with Eli Lilly. Lilly gains commercialization rights in exchange for a whopping $87 million up-front fee and milestones reaching up to $410 million. Report

> Denmark's Santaris Pharma has banked $30 million from its latest venture round. Report

> Up to now, researchers have been primarily interested in studying efficacy and safety in clinical trials. After today, you may have to start adding efficiency to the list of R&D focuses. Report

And Finally... By genetically engineering mice, scientists in Japan were able to switch off their fear of cats. Report